Sharief Taraman, Cognoa Inc.’s chief medical officer, has high hopes for using artificial intelligence and machine learning (AI/ML) to change the world of pediatric medicine. But he’s also wary that many of the disparities in the health care system today may become amplified in the medical software of tomorrow if developers are not careful.
In June the US Food and Drug Administration authorized Cognoa’s de novo for the Canvas Dx to help diagnose autism in children. The software as a medical device (SaMD) was expedited to market as a breakthrough device and even the agency touted its potential to help get treatment to autistic children sooner and give them a better chance of improved quality of life
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?